NCT03142724View on ClinicalTrials.gov

Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

March 1, 2018

Study Completion Date

March 1, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

[18F]MNI-968

Healthy volunteers recruited for the study will undergo a single \[18F\]MNI-968 injections and PET scans.

Trial Locations (1)

06510

Molecular NeuroImaging, LLC, New Haven

Sponsors
All Listed Sponsors
lead

Molecular NeuroImaging

OTHER